(P005) Excellent Locoregional Control but Modest Overall Survival Achieved in Patients With Inflammatory Breast Cancer

Publication
Article
OncologyOncology Vol 30 No 4_Suppl_1
Volume 30
Issue 4_Suppl_1

With aggressive trimodality therapy, excellent locoregional control was achieved in patients with newly diagnosed inflammatory breast cancer. However, DFS and OS are suboptimal, despite modern trimodality treatment.

Sana Rehman, MD, Anupama Chundury, MD, Michael Roach, MD, Parth Shah, Daniel Mullen, Todd DeWees, PhD, Laura Eschen, Maria Thomas, MD, PhD, Imran Zoberi, MD; Washington University

PURPOSE/OBJECTIVE: Inflammatory breast cancer (IBC) is an aggressive subtype of breast cancer with trimodality treatment established as the standard of care. We report our institutional outcomes for IBC incorporating comprehensive radiation therapy (RT).

MATERIALS AND METHODS: A retrospective review was conducted of 40 patients with newly diagnosed IBC who completed RT from 2003 to 2015. Radiation fields targeted the chest wall and regional lymph nodes (supraclavicular, axillary, and internal mammary lymph nodes). Locoregional control (LRC), disease-free survival (DFS), and overall survival (OS) were estimated with Kaplan-Meier curves. Patients were evaluated for risk factors predicting for OS utilizing Cox regression analysis.

RESULTS: Median follow-up time was 44 months (range: 8–122 mo). Median age was 50 years (range: 29–85 yr). All but three (7.5%) patients received neoadjuvant chemotherapy. Two (5%) patients underwent a lumpectomy, and the remainder underwent a mastectomy; all patients underwent axillary lymph node dissection. Eight (20%) patients had positive or close surgical margins. Twelve (30%) patients had triple-negative receptor status; 15 (38%) were human epidermal growth factor receptor 2 (HER2/neu)-amplified and received trastuzumab. All patients completed adjuvant RT, with 18 (45%) receiving three-dimensional (3D) conformal RT and 22 (55%) receiving intensity-modulated RT. The median dose delivered to the chest wall and lymph nodes was 5,040 cGy. Thirty-six (90%) patients received a boost to the chest wall (median: 1,000 cGy, range: 600–2,160 cGy). Eleven (28%) patients were treated with hyperthermia concurrent with RT. Five-year LRC, DFS, and OS rates were 89%, 57%, and 68%, respectively. On multivariate analysis, an increasing number of pathologically positive lymph nodes was predictive for worse OS (hazard ratio [HR], 1.18 [95% CI, 1.07–1.29]; P < .001).

CONCLUSIONS: With aggressive trimodality therapy, excellent LRC was achieved in patients with newly diagnosed IBC. However, DFS and OS are suboptimal, despite modern trimodality treatment.

Proceedings of the 98th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(S002) A 15-Year Review of Radiation Therapy for Keloids at Two Institutions
(S003) Single-Fraction Radiation Therapy for the Treatment of Multiple Myeloma Bony Metastases Provides Pain Control and Decreases Time to Chemotherapy
(S001) Prognostic Value of Pretreatment Serum Inflammatory Markers in Patients Receiving Radiation Therapy for Oropharyngeal Cancer
(S004) Trend in Second Malignancy Risk for Head and Neck Cancer With Increased Utilization of IMRT: Analysis of SEER Database
(S005) Comparison of Legal Needs of a Group of Patients With Cancer: Economic and Geographic Factors
(S006) Mission Improvement: Lessons From Initiating a Resident-Led Quality Improvement Project on Smoking Cessation at a County Hospital
(S007) Results of a Phase II Trial Using Cetuximab Plus Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
(S008) The Effect of Simulation and Treatment Delays for Patients With Oropharyngeal Cancer Receiving Definitive Radiation Therapy in the Era of Risk Stratification Using Smoking and Human Papilloma Virus Status
(S009) Intensity-Modulated Radiation Therapy With Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on Three-Year Toxicity
(S011) Comparative Study Between Ileal Conduit and Indiana Pouch After Cystectomy for Patients With Carcinoma of Urinary Bladder
(S010) Computed Tomography–Assessed Measures of Bone Mineral Density and Muscle Mass as Predictors of Survival in Men With Prostate Cancer
(S012) Quantitative Imaging to Evaluate the Malignant Potential of Pancreatic Cysts
(S013) Spine Stereotactic Radiosurgery With Concurrent Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
(S014) The Impact of Radiation Therapy on Survival in Surgically Resected, High-Risk Patients With Ampullary Adenocarcinoma: A Population-Based Analysis
(S016) The Impact of Stereotactic Body Radiation Therapy on Overall Survival in Patients With Locally Advanced Pancreatic Cancer

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Related Content